Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript

So there’s current basic users, who might do a lot of their procedures in certain parts of the knee. They can expand towards if they focus on the patella lesion. Now they have an option less invasive option for treating femoral condyle defects that certainly can is an instance where you take an experienced basic user and they start using it more broadly. So that can have very quick uptake as you might imagine. You also have new surgeons who because you take a biopsy and then the median time from biopsy to implant is roughly four months. There’s always a time lag there. So they’ll be kind of having a prospective, impact on the business there. So it’ll differ by segment, but again, you’re taking a well-known product with great clinical outcomes and operating surge using options were administered less invasively in an area of the need with the largest number of defects.

And so you could have very, pretty quick uptake for those who are interested in using MACI.

Unidentified Analyst: Great. Thanks guys.

Joe Mara: Thank you.

Nick Colangelo: Thank you.

Operator: This concludes the question-and-answer session. I would now like to turn it back to Nick Colangelo for closing remarks.

Nick Colangelo: Okay. Well, thanks. And thanks, everyone, for your questions and continued interest in Vericel. Obviously, the company had a great start to the year and we expect to deliver another full-year of strong financial and operating results in 2024. So we look forward to providing further updates on our next call and have a great day.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.